Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. (Q37270464)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18794889%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

review article

1 reference

title

Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18794889%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

0 references

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18794889%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Ralph Martins

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18794889%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

K A Bates

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18794889%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Q-X Li

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18794889%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

D Ames

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18794889%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

P Hudson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18794889%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

C L Masters

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18794889%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

language of work or name

English

0 references

publication date

16 September 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18794889%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18794889%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18794889%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18794889%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

page(s)

469-486

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18794889%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/mp.2008.96

14 January 2020

exact match

0 references

cites work

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught?

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide--the first step of a fatal cascade

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde".

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Release of excess amyloid beta protein from a mutant amyloid beta protein precursor.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43)

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Differential effects of the swedish mutant amyloid precursor protein on beta-amyloid accumulation and secretion in neurons and nonneuronal cells

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q24.3

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Alzheimer neuropathologic alterations in aged cognitively normal subjects.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

The amyloid hypothesis: let sleeping dogmas lie?

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

The severity of cortical Alzheimer's type changes is positively correlated with increased amyloid-beta Levels: Resolubilization of amyloid-beta with transition metal ion chelators

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Reduced levels of Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer's patients

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

A specific amyloid-beta protein assembly in the brain impairs memory

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Amyloid plaque imaging in vivo: current achievement and future prospects.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

PET imaging of amyloid deposition in patients with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Imaging beta-amyloid burden in aging and dementia.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Plasma amyloid beta protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Amyloid beta-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

CSF markers for Alzheimer's disease: Total tau, phospho-tau and Aβ42

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Engineered antibody fragments and the rise of single domains

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Epitope mapping and neuroprotective properties of a human single chain FV antibody that binds an internal epitope of amyloid-beta 1-42.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Advanced glycation end products: sparking the development of diabetic vascular injury

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Apolipoprotein E suppresses glial cell secretion of TNF alpha

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Atorvastatin-induced activation of Alzheimer's alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Plasma Abeta42 correlates positively with increased body fat in healthy individuals.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

APP intracellular domain is increased and soluble Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Changes in brain gene expression shared by scrapie and Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Purification and characterization of brain clusterin

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

SP-40,40 is a constituent of Alzheimer's amyloid

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Deposition of apolipoproteins E and J in senile plaques is topographically determined in both Alzheimer's disease and Down's syndrome brain

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Distribution of clusterin in Alzheimer brain tissue

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Clusterin (SGP-2): a multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Functional and structural properties of lipid-associated apolipoprotein J (clusterin).

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Apolipoprotein J and Alzheimer's amyloid beta solubility

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid beta

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Alpha2-macroglobulin attenuates beta-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Inhibition of Alzheimer beta-peptide fibril formation by serum amyloid P component.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

High density lipoproteins bind Aβ and apolipoprotein C-II amyloid fibrils

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Apolipoprotein E, A beta, and Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Apolipoprotein E: structure-function relationships

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Variation at the APOE -491 promoter locus is associated with altered brain levels of apolipoprotein E.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Association of human, rat, and rabbit apolipoprotein E with beta-amyloid

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Alzheimer's disease amyloid-beta peptide modulates apolipoprotein E isoform specific receptor binding.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Apolipoprotein E4 (ApoE4) but not ApoE3 or ApoE2 potentiates beta-amyloid protein activation of complement in vitro.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Blood-borne factors inhibit Alzheimer's beta-amyloid fibril formation in vitro.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Alpha2-macroglobulin deletion polymorphism and plasma levels in late onset Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Alpha-2 macroglobulin gene and Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Alpha2 macroglobulin and the risk of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

The alpha2-macroglobulin gene in AD: a population-based study and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

An alpha-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Alpha-2 macroglobulin polymorphism and Alzheimer disease risk in the UK.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Alpha-2 macroglobulin is genetically associated with Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Increased plasma concentration of serum amyloid P component in centenarians with impaired cognitive performance.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Plasma alpha1-antichymotrypsin in Alzheimer's disease; relationships with APOE genotypes

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Aggregation of amyloid beta-protein as function of age and apolipoprotein E in normal and Alzheimer's serum.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Systemic catabolism of Alzheimer's Abeta40 and Abeta42.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Circulating insulin-like growth factor I mediates effects of exercise on the brain.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Brain repair and neuroprotection by serum insulin-like growth factor I.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Insulin-Like growth factor I: implications in aging

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Neurodegeneration is associated to changes in serum insulin-like growth factors.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Serum insulin-like growth factor I regulates brain amyloid-beta levels.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease?

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Diabetes mellitus and the risk of dementia: The Rotterdam Study.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Abeta42 levels and risk for Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Amyloid beta antagonizes insulin promoted secretion of the amyloid beta protein precursor.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Neprilysin gene transfer reduces human amyloid pathology in transgenic mice.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Diagnostic accuracy of Alzheimer's disease: a neuropathological study.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Alzheimer disease as a vascular disorder: nosological evidence

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Insulin increases CSF Abeta42 levels in normal older adults

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

The role of gonadotropins in Alzheimer's disease: potential neurodegenerative mechanisms.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Coordinate regulation of the alpha(2)-macroglobulin signaling receptor and the low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor by insulin

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Memory improvement following induced hyperinsulinemia in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Insulin resistance, inflammation, and cognition in Alzheimer's Disease: lessons for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43).

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Biochemical diagnostic markers to detect early Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.96

7 January 2021

Identifiers

DOI

10.1038/MP.2008.96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18794889%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference